ROIV News and Press, Roivant Sciences Ltd. From 12/04/25

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – Scientists have engineered breakthrough cell therapies that can be mass-produced and stored ready-to-use, addressing key barriers in treatment access and cost [1] . Resear...

2025-12-02 10:53:04 ET Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. ( ARQT ) , rallied 27% to (at that time) a 38-month closing high of $24.95 after a stellar Q3 2025 report and initial FY 2026 sales guidance. The company’s pipeline-in-a-product, Zoryve, is g...

2025-11-21 11:15:29 ET More on markets Dividend Roundup: Nvidia, Home Depot, Nike, Johnson & Johnson, and more U.S. growth is set to reaccelerate in 2026, Apollo’s Slok notes Nasdaq and SGX forge a pathway for seamless U.S.–Singapore dual listings ...

2025-11-18 14:28:46 ET Roivant Sciences Ltd. (ROIV) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST... Read the full article on Seeking Alpha For further details see: Roivant Sciences Ltd. (ROIV) Presents at Jefferies London Healthcare Conference 2...

2025-11-14 17:28:43 ET More on 13F filings Seth Klarman's Baupost takes stake in Union Pacific, exits ViaSat, among Q3 trades Glenview adds new Pinterest, Zillow stakes, exits Wayfair, ON in Q3 moves Buffett's Berkshire Hathaway adds Google stake, exits D.R. Horton, ...

2025-11-13 07:28:33 ET Read the full article on Seeking Alpha For further details see: Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

2025-11-11 10:31:31 ET Roivant Sciences Ltd. (ROIV) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Roivant Sciences Ltd. (ROIV) Presents at Guggenheim Securiti...

2025-11-10 12:31:36 ET Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript

2025-11-10 08:01:44 ET More on Roivant Sciences Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript Roivant Science...

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update. Brepocitinib 30 mg demonstrated clinically meaningful and statistic...